ISCA2 and nonpapillary renal cell carcinoma: Significantly, ISCA2 inhibition through oral administration significantly inhibits tumor growth and is well tolerated at the therapeutic dose (Fig. 8A–E), providing proof-of-concept for the efficacy and safety of ISCA2 inhibition for the treatment of ccRCC and other HIF driven and/or ferroptosis susceptible cancers.